MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
cepii_allergie.png
 
 
 
Hauptnavigation
  • Home
  • Allgemeine Informationen
  • Forschung
  • Studium & Lehre
  • FachärztInnenausbildung
 
IPA / Single View
 
Subnavigation

Research News

 

Isolation of nanobodies with potential to reduce patients' IgE binding to the major birch pollen allergen, Bet v 1

Ines Zettl, Tatiana Ivanova, Maria R. Strobl, Christina Weichwald, Oksana Goryainova, Evgenia Khan, Marina V. Rutovskaya, Margarete Focke- Tejkl, Anja Drescher, Barbara Bohle, Sabine Flicker, Sergei V. Tillib Allergy 2022...[more]

 

Impaired Mineral Ion Metabolism in a Mouse Model of Targeted Calcium-Sensing Receptor (CaSR) Deletion from Vascular Smooth Muscle Cells

Martin Schepelmann (group Enikö Kallay) and national and international colleagues and collaborators have just published a study in the Journal of the American Society of Nephrology (JASN), one of the highest ranked and most...[more]

 

Vaccine based on folded RBD-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants

The preclinical data for a vaccine developed at MedUni Vienna to protect against SARS-CoV-2 indicates that it is effective against all SARS-CoV-2 variants known to date, including omicron - even in those who have not yet built up...[more]

 

Birch pollen allergic patients have IgE and IgG antibodies binding to diverse patterns of conformational epitopes on the major allergen, Bet v 1

Schmalz S, Mayr V, Shosherova A, Gepp B, Ackerbauer D, Sturm G, Bohle B, Breiteneder H, Radauer C. Isotype-specific binding patterns of serum antibodies to multiple conformational epitopes of Bet v 1.[more]

 

Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.

Gattinger P, Niespodziana K, Stiasny K, Sahanic S, Tulaeva I, Borochova K, Dorofeeva Y, Schlederer T, Sonnweber T, Hofer G, Kiss R, Kratzer B, Trapin D, Tauber PA, Rottal A, Körmöczi U, Feichter M, Weber M, Focke-Tejkl M,...[more]

 

Stereo-Specific Modulation of the Extracellular Calcium-Sensing Receptor in Colon Cancer Cells

Martin Schepelmann, Nadja Kupper, Marta Sladczyk, Bethan Mansfield, Teresa Manhardt, Karina Piatek, Luca Iamartino, Daniela Riccardi, Benson M. Kariuki, Marcella Bassetto, and Enikö Kallay Stereo-Specific Modulation of the...[more]

 

Amirreza Mahbod, Post-Doc in the group of Isabella Ellinger, has achieved PLACE 1 in the leaderboard of the MICCAI 2021 Foot Ulcer Segmentation Challenge.

Foot ulcer is a common complication of diabetes mellitus; it is associated with substantial morbidity and mortality and remains a major risk factor for lower leg amputation. Extracting accurate morphological features from the...[more]

 
Displaying results 1 to 7 out of 96
<< First < Previous 1 2 3 4 5 6 7 Next > Last >>
 
Inhaltsbereich

Vaccine based on folded RBD-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants

The preclinical data for a vaccine developed at MedUni Vienna to protect against SARS-CoV-2 indicates that it is effective against all SARS-CoV-2 variants known to date, including omicron - even in those who have not yet built up any immunity as a result of vaccination (non-responders). The data from the study were recently published in the leading journal "Allergy".

The antigen-based vaccine developed in the Department of Pathophysiology and Allergy Research in the group of Rudolf Valenta targets the receptor binding domains (RBD) of the SARS-CoV-2 virus and induced a robust and uniform RBD-specific IgG antibody response in animal models and in human tests. This antibody response prevents the virus from docking onto and entering the body's cells, so that infection cannot occur.

Combination of coronavirus vaccine and hepatitis B vaccine

The SARS-CoV-2 subunit vaccine (PreS-RBD) is based on a structurally folded fusion protein consisting of two receptor binding domains (RBD) of the SARS-CoV-2 virus and the PreS antigen from hepatitis B, which serve as immunological carriers for each other, thereby strengthening the immune response. The PreS-RBD vaccine induced RBD-specific IgG antibodies consisting of an early IgG1 and sustained IgG4 antibody response. 

PreS-RBD-specific IgG antibodies detected in blood and mucosal secretions reacted with SARS-CoV-2 variants, including the omicron variant. Antibodies induced by vaccination with PreS-RBD more potently inhibited the binding of RBD with its human receptor ACE2, and their virus-neutralizing titers were higher than those in a random sample of individuals fully immunized with two vaccinations of currently registered vaccines or than those of COVID-19 convalescents (i.e., individuals who had previously had COVID-19).

Immunity even for previous "non-responders"

The PreS-RBD vaccine has the potential to induce sterilizing immunity to old and new SARS-CoV-2 variants by preventing infection by stopping viral replication and transmission through the inhibition of cellular virus entry. Moreover, it is expected that the vaccine will even be effective in people who have not previously responded to vaccination ("RBD non-responders"), as they will receive additional T-cell support from the PreS portion of the vaccine. 

Results based on decades of experience from allergy research at MedUni Vienna
The development of this COVID-19 vaccine was to a large extent inspired by decades of experience in allergy vaccine design. Previous work on allergy vaccines and clinical trials also conducted with PreS-based allergy vaccines have demonstrated the safety of PreS-based vaccines, even when used repeatedly.
 

Vaccine based on folded RBD-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants
Gattinger, P., Kratzer, B., Tulaeva, I., Niespodziana, K., Ohradanova-Repic, A., Gebetsberger, L., Borochova, K., Garner-Spitzer, E., Trapin, D., Hofer, G., Keller, W., Baumgartner, I., Tancevski, I., Khaitov, M., Karaulov, A., Stockinger, H., Wiedermann, U., Pickl, W.F. and Valenta, R. (2022), Vaccine based on folded RBD-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants. Allergy
https://doi.org/10.1111/all.15305 

https://www.youtube.com/watch?v=NDLquxPzoI4

 

 

 
 
Drucken
 

Schnellinfo

 
-- Green IPA
-- Technology Platforms
-- Kontakt
-- News (Archiv)
-- Seminare
-- Social Life
-- Intranet Login
-- QM-Dokumente (Intranet)
-- Bildergalerie (Intranet)
-- Alumni
-- Links
 
 

Featured

 
 
 
© MedUni Wien  | 
 Impressum | Nutzungsbedingungen | Datenschutzerklärung | Barrierefreiheit | Kontakt